US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
US4002531A
(en)
|
1976-01-22 |
1977-01-11 |
Pierce Chemical Company |
Modifying enzymes with polyethylene glycol and product produced thereby
|
US6936694B1
(en)
|
1982-05-06 |
2005-08-30 |
Intermune, Inc. |
Manufacture and expression of large structural genes
|
US4572208A
(en)
|
1983-06-29 |
1986-02-25 |
Utah Medical Products, Inc. |
Metabolic gas monitoring apparatus and method
|
US4703008A
(en)
|
1983-12-13 |
1987-10-27 |
Kiren-Amgen, Inc. |
DNA sequences encoding erythropoietin
|
KR850004274A
(ko)
|
1983-12-13 |
1985-07-11 |
원본미기재 |
에리트로포이에틴의 제조방법
|
NZ210501A
(en)
|
1983-12-13 |
1991-08-27 |
Kirin Amgen Inc |
Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
|
US6319685B1
(en)
|
1984-09-27 |
2001-11-20 |
Unigene Laboratories, Inc. |
Alpha-amidating enzyme compositions and processes for their production and use
|
FI78231C
(fi)
|
1984-11-21 |
1989-07-10 |
Instrumentarium Oy |
Maetanordning foer metaboliska storheter anslutbar till en respirator.
|
US4695463A
(en)
|
1985-05-24 |
1987-09-22 |
Warner-Lambert Company |
Delivery system for active ingredients and preparation thereof
|
US4766106A
(en)
|
1985-06-26 |
1988-08-23 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polymer conjugation
|
US4810643A
(en)
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
JPS63500636A
(ja)
|
1985-08-23 |
1988-03-10 |
麒麟麦酒株式会社 |
多分化能性顆粒球コロニー刺激因子をコードするdna
|
US4904584A
(en)
|
1987-12-23 |
1990-02-27 |
Genetics Institute, Inc. |
Site-specific homogeneous modification of polypeptides
|
US5075222A
(en)
|
1988-05-27 |
1991-12-24 |
Synergen, Inc. |
Interleukin-1 inhibitors
|
CA2006596C
(en)
|
1988-12-22 |
2000-09-05 |
Rika Ishikawa |
Chemically-modified g-csf
|
US5166322A
(en)
|
1989-04-21 |
1992-11-24 |
Genetics Institute |
Cysteine added variants of interleukin-3 and chemical modifications thereof
|
WO1991005795A1
(en)
|
1989-10-16 |
1991-05-02 |
Amgen Inc. |
Stem cell factor
|
US5372808A
(en)
|
1990-10-17 |
1994-12-13 |
Amgen Inc. |
Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
|
HU222249B1
(hu)
|
1991-03-08 |
2003-05-28 |
Amylin Pharmaceuticals Inc. |
Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
|
DK0578774T3
(da)
|
1991-04-05 |
1999-04-26 |
Univ Washington |
Monoklonale antistoffer mod stamcellefaktor-receptorer
|
NZ244778A
(en)
|
1991-10-21 |
1994-03-25 |
Ortho Pharma Corp |
Peg imidates and protein derivatives thereof
|
US5912015A
(en)
|
1992-03-12 |
1999-06-15 |
Alkermes Controlled Therapeutics, Inc. |
Modulated release from biocompatible polymers
|
US5581476A
(en)
|
1993-01-28 |
1996-12-03 |
Amgen Inc. |
Computer-based methods and articles of manufacture for preparing G-CSF analogs
|
US5766627A
(en)
|
1993-11-16 |
1998-06-16 |
Depotech |
Multivescular liposomes with controlled release of encapsulated biologically active substances
|
US6288030B1
(en)
|
1993-12-22 |
2001-09-11 |
Amgen Inc. |
Stem cell factor formulations and methods
|
US6048837A
(en)
|
1994-08-17 |
2000-04-11 |
The Rockefeller University |
OB polypeptides as modulators of body weight
|
US6001968A
(en)
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
US6309853B1
(en)
|
1994-08-17 |
2001-10-30 |
The Rockfeller University |
Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
|
US5824784A
(en)
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
US5827734A
(en)
|
1995-01-20 |
1998-10-27 |
University Of Washington |
Materials and methods for determining ob protein in a biological sample
|
EP0725078A1
(en)
|
1995-01-31 |
1996-08-07 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5567803A
(en)
|
1995-01-31 |
1996-10-22 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5691309A
(en)
|
1995-01-31 |
1997-11-25 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5532336A
(en)
|
1995-01-31 |
1996-07-02 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5563245A
(en)
|
1995-01-31 |
1996-10-08 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5559208A
(en)
|
1995-01-31 |
1996-09-24 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5525705A
(en)
|
1995-01-31 |
1996-06-11 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5605886A
(en)
|
1995-01-31 |
1997-02-25 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5580954A
(en)
|
1995-01-31 |
1996-12-03 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5552523A
(en)
|
1995-01-31 |
1996-09-03 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5569743A
(en)
|
1995-01-31 |
1996-10-29 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5594104A
(en)
|
1995-01-31 |
1997-01-14 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5552524A
(en)
|
1995-01-31 |
1996-09-03 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5563244A
(en)
|
1995-01-31 |
1996-10-08 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5574133A
(en)
|
1995-01-31 |
1996-11-12 |
Eli Lilly And Company |
Anti-obesity proteins
|
AU4766596A
(en)
|
1995-01-31 |
1996-08-21 |
Eli Lilly And Company |
Ob gene product antibodies
|
JPH11501297A
(ja)
|
1995-01-31 |
1999-02-02 |
イーライ・リリー・アンド・カンパニー |
抗肥満症タンパク質
|
US5552522A
(en)
|
1995-01-31 |
1996-09-03 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5569744A
(en)
|
1995-01-31 |
1996-10-29 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5521283A
(en)
|
1995-01-31 |
1996-05-28 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5567678A
(en)
|
1995-01-31 |
1996-10-22 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5563243A
(en)
|
1995-01-31 |
1996-10-08 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5554727A
(en)
|
1995-01-31 |
1996-09-10 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5594101A
(en)
|
1995-03-03 |
1997-01-14 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5719266A
(en)
|
1995-03-17 |
1998-02-17 |
Eli Lilly And Company |
Anti-obesity proteins
|
EP0736599A3
(en)
|
1995-04-03 |
1996-12-11 |
Takeda Chemical Industries Ltd |
The rat obesity gene, its gene product and its production
|
WO1996031526A1
(en)
|
1995-04-06 |
1996-10-10 |
Amylin Pharmaceuticals, Inc. |
Anti-obesity agents
|
US5614379A
(en)
|
1995-04-26 |
1997-03-25 |
Eli Lilly And Company |
Process for preparing anti-obesity protein
|
US5840517A
(en)
*
|
1995-04-26 |
1998-11-24 |
Eli Lilly And Company |
Process for preparing obesity protein analogs
|
GB9509164D0
(en)
|
1995-05-05 |
1995-06-28 |
Smithkline Beecham Plc |
Novel compounds
|
DE741187T1
(de)
|
1995-05-05 |
1997-04-30 |
Hoffmann La Roche |
Rekombinante Obesitäts-(OB)-Proteine
|
CA2218529A1
(en)
|
1995-05-08 |
1996-11-14 |
Chiron Corporation |
Nucleic acids for treating obesity
|
AU5800696A
(en)
|
1995-05-26 |
1996-12-11 |
Eli Lilly And Company |
Rhesus ob protein and dna
|
AU6028396A
(en)
|
1995-06-07 |
1996-12-30 |
Amgen, Inc. |
Ob protein compositions and method
|
US5581005A
(en)
|
1995-06-16 |
1996-12-03 |
The Procter & Gamble Company |
Method for manufacturing cobalt catalysts
|
AU6284896A
(en)
|
1995-06-22 |
1997-01-22 |
Eli Lilly And Company |
Obesity protein intermediates and their preparation and use
|
GB2302559B
(en)
|
1995-06-23 |
1998-06-03 |
Draftex Ind Ltd |
Opening arrangements and methods for closure members
|
CA2224381A1
(en)
|
1995-06-27 |
1997-01-16 |
Takeda Chemical Industries, Ltd. |
Method of producing sustained-release preparation
|
CA2225454A1
(en)
*
|
1995-06-30 |
1997-01-23 |
Thomas Wesley Stephens |
Methods for treating diabetes
|
CA2229450A1
(en)
|
1995-08-17 |
1997-02-27 |
Amgen Inc. |
Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions
|
WO1997016550A1
(en)
|
1995-11-02 |
1997-05-09 |
Bristol-Myers Squibb Company |
Polypeptide fragments derived from the obese gene product
|
NZ511617A
(en)
|
1995-11-22 |
2003-08-29 |
Amgen Inc |
DNA encoding OB protein and uses thereof
|
US6936439B2
(en)
|
1995-11-22 |
2005-08-30 |
Amgen Inc. |
OB fusion protein compositions and methods
|
AU1406497A
(en)
|
1995-12-06 |
1997-06-27 |
Schering Corporation |
Mutational variants of mammalian ob gene proteins
|
US6369027B1
(en)
|
1995-12-22 |
2002-04-09 |
Amgen Inc. |
Osteoprotegerin
|
GB9526733D0
(en)
*
|
1995-12-30 |
1996-02-28 |
Delta Biotechnology Ltd |
Fusion proteins
|
EP0877627A1
(en)
|
1996-01-25 |
1998-11-18 |
Eli Lilly And Company |
Obesity protein analog compounds and formulations thereof
|
US6013009A
(en)
|
1996-03-12 |
2000-01-11 |
Karkanen; Kip Michael |
Walking/running heart rate monitoring system
|
WO1997038014A1
(en)
|
1996-04-04 |
1997-10-16 |
Amgen Inc. |
Fibulin pharmaceutical compositions and related methods
|
US6025324A
(en)
|
1996-05-15 |
2000-02-15 |
Hoffmann-La Roche Inc. |
Pegylated obese (ob) protein compositions
|
CA2257240A1
(en)
|
1996-06-06 |
1997-12-11 |
Smithkline Beecham P.L.C. |
Fragments of leptin (ob protein)
|
US5922678A
(en)
|
1996-06-28 |
1999-07-13 |
Eli Lilly And Company |
Methods for treating diabetes
|
AU4237797A
(en)
|
1996-08-30 |
1998-03-19 |
Amgen, Inc. |
Methods of increasing sensitivity of an individual to OB protein by upregula ting OB protein receptor
|
CN1230966A
(zh)
|
1996-09-20 |
1999-10-06 |
赫彻斯特股份公司 |
勒帕素拮抗剂在用于治疗ii型糖尿病胰岛素耐受性中的用途
|
WO1998016545A1
(en)
|
1996-10-11 |
1998-04-23 |
Eli Lilly And Company |
Therapeutic proteins
|
WO1998024896A2
(en)
|
1996-12-06 |
1998-06-11 |
F. Hoffmann-La Roche Ag |
Muteins of obese protein
|
EA004791B1
(ru)
|
1996-12-20 |
2004-08-26 |
Амген Инк. |
Композиции на основе слитого белка ob и способы их применения
|
US6309360B1
(en)
|
1997-03-17 |
2001-10-30 |
James R. Mault |
Respiratory calorimeter
|
WO1998041222A1
(en)
*
|
1997-03-20 |
1998-09-24 |
Eli Lilly And Company |
Obesity protein formulations
|
AU2951797A
(en)
|
1997-06-06 |
1998-12-21 |
Smithkline Beecham Plc |
Use of leptin antagonists for the treatment of diabetes
|
DE69828287T2
(de)
|
1997-06-13 |
2005-12-15 |
Gryphon Therapeutics, Inc., South San Francisco |
Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen
|
US6538194B1
(en)
|
1998-05-29 |
2003-03-25 |
Catalysts & Chemicals Industries Co., Ltd. |
Photoelectric cell and process for producing metal oxide semiconductor film for use in photoelectric cell
|
JP4199421B2
(ja)
|
1998-08-10 |
2008-12-17 |
アムジエン・インコーポレーテツド |
デキストラン−レプチン結合体、医薬組成物および関連方法
|
CA2344623A1
(en)
|
1998-10-02 |
2000-04-13 |
Amgen Inc. |
Method to determine a predisposition to leptin treatment
|
US6420339B1
(en)
|
1998-10-14 |
2002-07-16 |
Amgen Inc. |
Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US6194006B1
(en)
|
1998-12-30 |
2001-02-27 |
Alkermes Controlled Therapeutics Inc. Ii |
Preparation of microparticles having a selected release profile
|
ES2343072T3
(es)
|
1999-01-14 |
2010-07-22 |
Amylin Pharmaceuticals, Inc. |
Exendina para la supresion del glucagon.
|
DK1151102T3
(da)
|
1999-02-12 |
2006-05-29 |
Amgen Inc |
Glycosylerede leptinpræparater og relaterede fremgangsmåder
|
US6475984B2
(en)
*
|
1999-04-29 |
2002-11-05 |
The Nemours Foundation |
Administration of leptin
|
TW514510B
(en)
|
1999-06-11 |
2002-12-21 |
Tanita Seisakusho Kk |
Method and apparatus for measuring distribution of body fat
|
US6468222B1
(en)
|
1999-08-02 |
2002-10-22 |
Healthetech, Inc. |
Metabolic calorimeter employing respiratory gas analysis
|
US6258932B1
(en)
|
1999-08-09 |
2001-07-10 |
Tripep Ab |
Peptides that block viral infectivity and methods of use thereof
|
EP1214351A2
(en)
*
|
1999-09-22 |
2002-06-19 |
Genset |
Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases
|
US6530886B1
(en)
|
1999-10-08 |
2003-03-11 |
Tanita Corporation |
Method and apparatus for measuring subcutaneous fat using ultrasonic wave
|
US7057015B1
(en)
*
|
1999-10-20 |
2006-06-06 |
The Salk Institute For Biological Studies |
Hormone receptor functional dimers and methods of their use
|
JP2001199887A
(ja)
|
1999-11-10 |
2001-07-24 |
Takeda Chem Ind Ltd |
体重増加抑制剤
|
PL356745A1
(en)
|
1999-11-10 |
2004-06-28 |
Takeda Chemical Industries, Ltd |
Body weight gain inhibitors
|
US20050287153A1
(en)
*
|
2002-06-28 |
2005-12-29 |
Genentech, Inc. |
Serum albumin binding peptides for tumor targeting
|
US7157564B1
(en)
|
2000-04-06 |
2007-01-02 |
Affymetrix, Inc. |
Tag nucleic acids and probe arrays
|
AU2001259063A1
(en)
*
|
2000-04-12 |
2001-10-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US6264987B1
(en)
|
2000-05-19 |
2001-07-24 |
Alkermes Controlled Therapeutics Inc. Ii |
Method for preparing microparticles having a selected polymer molecular weight
|
TW515705B
(en)
|
2000-05-31 |
2003-01-01 |
Yamato Scale Co Ltd |
Visceral fat meter
|
US6492117B1
(en)
|
2000-07-12 |
2002-12-10 |
Gendaq Limited |
Zinc finger polypeptides capable of binding DNA quadruplexes
|
US6296842B1
(en)
|
2000-08-10 |
2001-10-02 |
Alkermes Controlled Therapeutics, Inc. |
Process for the preparation of polymer-based sustained release compositions
|
US6475158B1
(en)
|
2000-10-24 |
2002-11-05 |
Korr Medical Technologies, Inc. |
Calorimetry systems and methods
|
PL214862B1
(pl)
|
2001-10-22 |
2013-09-30 |
Amgen |
Sposób in vitro do okreslania predyspozycji pacjenta ludzkiego z lipoatrofia do reagowania na leczenie bialkiem leptyny, kompozycje farmaceutyczne do zastosowania do leczenia lipoatrofii i kompozycje farmaceutyczne zawierajace bialko leptyny
|
US6899892B2
(en)
|
2001-12-19 |
2005-05-31 |
Regents Of The University Of Minnesota |
Methods to reduce body fat
|
EP1463751B1
(en)
|
2001-12-21 |
2013-05-22 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
AU2003290563A1
(en)
|
2002-10-31 |
2004-05-25 |
Clf Medical Technology Acceleration Program, Inc. |
Leptin-related peptides
|
KR20050084751A
(ko)
|
2002-11-01 |
2005-08-29 |
가부시끼가이샤 도꾸야마 |
중합성 조성물, 그의 경화체의 제조법 및 광학 물품
|
TW200526254A
(en)
*
|
2003-09-19 |
2005-08-16 |
Novo Nordisk As |
Novel GLP-1 derivatives
|
WO2005028516A2
(en)
*
|
2003-09-19 |
2005-03-31 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
US8263084B2
(en)
|
2003-11-13 |
2012-09-11 |
Hanmi Science Co., Ltd |
Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
|
US8114958B2
(en)
|
2004-02-11 |
2012-02-14 |
Amylin Pharmaceuticals, Inc. |
Amylin family peptides
|
US7399744B2
(en)
|
2004-03-04 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Methods for affecting body composition
|
US8394765B2
(en)
|
2004-11-01 |
2013-03-12 |
Amylin Pharmaceuticals Llc |
Methods of treating obesity with two different anti-obesity agents
|
CA2589800A1
(en)
|
2004-12-02 |
2006-06-08 |
Domantis Limited |
Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
|
US7898623B2
(en)
|
2005-07-04 |
2011-03-01 |
Semiconductor Energy Laboratory Co., Ltd. |
Display device, electronic device and method of driving display device
|
GB0524788D0
(en)
*
|
2005-12-05 |
2006-01-11 |
Affibody Ab |
Polypeptides
|
US20070238669A1
(en)
|
2006-01-11 |
2007-10-11 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes related conditions
|
US8486890B2
(en)
|
2006-03-15 |
2013-07-16 |
Novo Nordisk A/S |
Amylin derivatives
|
EP2010208A1
(en)
|
2006-03-31 |
2009-01-07 |
Amylin Pharmaceuticals, Inc. |
Amylin and amylin agonists for treating psychiatric diseases and disorders
|
EA200870575A1
(ru)
|
2006-05-26 |
2009-08-28 |
Амилин Фармасьютикалз, Инк. |
Композиции и способы лечения застойной сердечной недостаточности
|
US20100022457A1
(en)
|
2006-05-26 |
2010-01-28 |
Bristol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
JP2008169195A
(ja)
|
2007-01-05 |
2008-07-24 |
Hanmi Pharmaceutical Co Ltd |
キャリア物質を用いたインスリン分泌ペプチド薬物結合体
|
CN101113175A
(zh)
*
|
2007-04-28 |
2008-01-30 |
中国科学院西北高原生物研究所 |
鼠兔家族瘦素蛋白及其cDNA序列
|
JP2009019027A
(ja)
|
2007-07-16 |
2009-01-29 |
Hanmi Pharmaceutical Co Ltd |
アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
|
CN104710518A
(zh)
|
2007-07-31 |
2015-06-17 |
阿菲博迪公司 |
新白蛋白结合组合物、方法及应用
|
GB0715216D0
(en)
|
2007-08-03 |
2007-09-12 |
Asterion Ltd |
Leptin
|
EP2036923A1
(en)
|
2007-09-11 |
2009-03-18 |
Novo Nordisk A/S |
Improved derivates of amylin
|
WO2009042922A2
(en)
*
|
2007-09-27 |
2009-04-02 |
Amylin Pharmaceuticals, Inc. |
Peptide-peptidase inhibitor conjugates and methods of making and using same
|
MX2010005345A
(es)
|
2007-11-14 |
2010-08-31 |
Amylin Pharmaceuticals Inc |
Metodos para el tratamiento de la obesidad y enfermedades y trastornos relacionados con la obesidad.
|
SG188143A1
(en)
*
|
2008-02-08 |
2013-03-28 |
Ambrx Inc |
Modified leptin polypeptides and their uses
|
WO2009149379A2
(en)
|
2008-06-05 |
2009-12-10 |
Regents Of The University Of Michigan |
Use of leptin for the treatment of fatty liver diseases and conditions
|
WO2010046357A1
(en)
|
2008-10-21 |
2010-04-29 |
Novo Nordisk A/S |
Amylin derivatives
|
WO2010054699A1
(en)
*
|
2008-11-17 |
2010-05-20 |
Affibody Ab |
Conjugates of albumin binding domain
|
JP5753097B2
(ja)
|
2009-01-22 |
2015-07-22 |
ユニジーン・ラボラトリーズ・インコーポレーテッド |
肥満の治療
|
MX362028B
(es)
|
2009-02-03 |
2019-01-04 |
Amunix Pharmaceuticals Inc |
Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
|
JP6143297B2
(ja)
*
|
2010-06-04 |
2017-06-07 |
チウムバイオ・カンパニー・リミテッドTiumBio Co., Ltd. |
第vii因子活性を有する融合タンパク質
|
NZ604805A
(en)
|
2010-07-09 |
2014-09-26 |
Affibody Ab |
Polypeptides
|
CN103370083B
(zh)
|
2010-09-28 |
2016-11-16 |
艾米琳制药有限责任公司 |
具有增强的作用持续时间的工程化多肽
|
DK3241558T3
(da)
|
2010-09-28 |
2021-04-26 |
Aegerion Pharmaceuticals Inc |
Højopløselige leptiner
|
ES2732475T3
(es)
*
|
2011-07-08 |
2019-11-22 |
Aegerion Pharmaceuticals Inc |
Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida
|
WO2013009545A1
(en)
|
2011-07-08 |
2013-01-17 |
Amylin Pharmaceuticals, Inc. |
Engineered polypeptides having enhanced duration of action with reduced immunogenicity
|